Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Fetal Diagnosis and Therapy

• Publication date

  2016-03-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000444450PMID 26930075
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.

  2016cited by this paper
• Competing risks model in screening for preeclampsia by maternal characteristics and medical history.

  2015cited by this paper
• Prediction and prevention of early‐onset pre‐eclampsia: impact of aspirin after first‐trimester screening

  2015cited by this paper
• Preeclampsia and Maternal Cardiovascular Disease: Consequence or Predisposition?

  2014cited by this paper
• Cardiovascular Implications in Preeclampsia: An Overview

  2014cited by this paper
• Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia

  2014cited by this paper
• Serious preeclampsia among different immigrant groups.

  2012cited by this paper
• Combined Screening for Preeclampsia and Small for Gestational Age at 11–13 Weeks

  2012cited by this paper
• A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia.

  2012cited by this paper
• The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients.

  2012cited by this paper
• Placenta-bound and body fluid PP13 and its mRNA in normal pregnancy compared to preeclampsia, HELLP and preterm delivery.

  2011cited by this paper
• Prediction of early, intermediate and late pre‐eclampsia from maternal factors, biophysical and biochemical markers at 11–13 weeks

  2011cited by this paper
• Evaluation and management of severe preeclampsia before 34 weeks' gestation.

  2011cited by this paper
• Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?

  2011cited by this paper
• Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11–13 weeks

  2010cited by this paper
• ASH Position Paper: Hypertension in Pregnancy

  2009cited by this paper
• American Society of Hypertension. ASH Position Paper: Hypertension in Pregnancy

  2009cited by this paper
• Fetal-Maternal Conflict, Trophoblast Invasion, Preeclampsia, and the Red Queen

  2008cited by this paper
• Placental Origins of Preeclampsia: Challenging the Current Hypothesis

  2008cited by this paper
• A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate

  2008cited by this paper
• Circulating microparticles in normal pregnancy and pre-eclampsia.

  2008cited by this paper
• Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre‐eclampsia

  2007cited by this paper
• Prediction of pre‐eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy‐associated plasma protein‐A, free β‐human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation

  2006cited by this paper
• Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction.

  2006cited by this paper
• A comparative study of the effect of three different syncytiotrophoblast micro-particles preparations on endothelial cells.

  2005cited by this paper
• Make every mother and child count.

  2005cited by this paper
• Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

  2002cited by this paper
• Diagnosis and management of preeclampsia and eclampsia

  2002cited by this paper
• Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

  2002cited by this paper
• The Classification and Diagnosis of the Hypertensive Disorders of Pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP)

  2001cited by this paper
• "Congo" red: out of Africa?

  2001cited by this paper
• Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US.

  1992cited by this paper
• The classification and definition of the hypertensive disorders of pregnancy.

  1988cited by this paper
• ON THE BINDING OF CONGO RED BY AMYLOID

  1962cited by this paper

• Clinical value of urinary misfolded protein and serum markers in preeclampsia: a descriptive longitudinal study.

  2026cites this paper
• Validation of urinary Congo Red preeclampsia detection point-of-care devise.

  2024cites this paper
• Comparing urine point‐of‐care tests to screen preeclampsia: Congo‐red dot paper test versus dipstick urinalysis

  2024cites this paper
• CercaTest Red, a novel urine-based point-of-care test for the detection of preeclampsia

  2024cites this paper
• Protein Misfolding in Pregnancy: Current Insights, Potential Mechanisms, and Implications for the Pathogenesis of Preeclampsia

  2024cites this paper
• The effectiveness of the Congo Red Dot paper test in hypertensive disorders of pregnancy: A systematic review and meta-analysis

  2023cites this paper
• A Study of Role of Urinary Congophilia in Early Detection of Preeclampsia

  2022cites this paper
• New approaches in predicting and diagnosing preeclampsia: Congo Red Dot Paper Test (Review).

  2022influential citation
• Screening for late preeclampsia at 35–37 weeks by the urinary Congo-red dot paper test

  2021cites this paper
• Congo red test for identification of preeclampsia: Results of a prospective diagnostic case-control study in Bangladesh and Mexico

  2020cites this paper
• The high-resolution mass spectrometry study of the protein composition of amyloid-like urine aggregates associated with preeclampsia

  2020cites this paper
• Late pregnancy screening for preeclampsia with a urinary point-of-care test for misfolded proteins

  2020cites this paper
• Congo Red Dot Paper Test for Antenatal Triage and Rapid Identification of Preeclampsia

  2019cites this paper
• Exploring strengths and limits of urinary D-chiro inositol phosphoglycans (IPG-P) as a screening test for preeclampsia: A systematic review and meta-analysis.

  2019cites this paper
• Evaluation of Congo red staining kit to determine proteinuria in preeclampsia

  2018cites this paper
• Efficacy of low dose aspirin on maternal and foetal outcome in preeclampsia

  2017cites this paper
• Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings.

  2017cites this paper
• Preeclampsia-Eclampsia Adverse Outcomes Reduction: The Preeclampsia-Eclampsia Checklist

  2016influential citation
• Are We Getting Closer to Explaining Preeclampsia?

  2016cites this paper